\(
\def\WIPO{World Intellectual Property Organisation}
\)
From "specified in the claims" to "ascertaining the patent's technical contribution" in SPC eligibility: challenging the patent bargain and the effects on pharmaceutical innovation
2026
Formatos
| Formato | |
|---|---|
| BibTeX | |
| MARCXML | |
| TextMARC | |
| MARC | |
| DataCite | |
| DublinCore | |
| EndNote | |
| NLM | |
| RefWorks | |
| RIS | |
Título
From "specified in the claims" to "ascertaining the patent's technical contribution" in SPC eligibility: challenging the patent bargain and the effects on pharmaceutical innovation
Tipo de elemento
Journal article
Descripción
1 online resource
Resúmen
Patent protection of 20 years may suffice for simple mechanical inventions, but not for drugs. There, the path to discovery leads from in-vitro animal testing, and human trials, to approval by regulatory bodies, all before marketing becomes possible. While the profits of a successful medicine may be transformative, the pathway to exploitation markedly truncates the time for making use of the patent monopoly. Typically, medicinal development and approval exhausts 12 years from patent registration. The exceptional speed of vaccine approval for the world-wide emergency which was the Covid-19 pandemic5 is deceptive, as most putative drugs fail before they reach the point of seeking approval for market release.
Source of Description
Crossref
Serie
Intellectual Property Quarterly ; I.P.Q. 2026, 2, 81-108
Recursos vinculados
Publicado
[New York, NY] : Thomson Reuters, 2026.
Lengua(s)
eng
Derechos de autor
https://1.next.westlaw.com/Copyright
El registro aparece en